Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intradetrusor Dysport for urinary incontinence due to neurogenic detrusor overactivity
2015-003471-30Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in detrusor hyperreflexia (DH) and urinary incontinence (UI) (3 arms), sponsored by Ipsen. Primary endpoint: Mean change in weekly urinary incontinence episodes at Week 6. Started Feb 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)
Beyond the preview
Go deeper on 2015-003471-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003471-30.